Connect with us

Technology

Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore

Published

on

Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease

SINGAPORE, July 18, 2024 /PRNewswire/ — With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the general population. The increase in life expectancy has raised interest and discussion regarding the quality of life of PWH and the management of chronic diseases. Gilead Sciences, with the support of a number of Singapore and Hong Kong community-based organizations, conducted research on PWH’s perceptions of health management and quality of life. The research identified three blind spots that affect the quality of life among PWH to improve their overall health, including 1) most PWH prioritize short-term physical health over mental and psychosocial health, 2) PWH have low awareness of chronic diseases such as cardiovascular and other conditions, 3) PWH are relatively passive when communicating with healthcare professionals. These blind spots could lead to negative impacts on the overall HIV treatment outcomes, affecting the physical and mental health of PWH.

While the UNAIDS 95-95-95 targets (which call for 95% of PWH to know their HIV status, 95% of PWH to be on antiretroviral therapy, and 95% PWH on antiretroviral therapy to have suppressed viral loads [see note]) aim to end AIDS as a public health threat, experts have also proposed the fourth ’90’ which brings attention to PWH’s long-term health management and quality of life[2,3]. In light of this, Gilead Sciences’ in-depth qualitative research was conducted between February and May 2022 in Singapore and Hong Kong. In Singapore, a total of 30 respondents who were receiving HIV treatment and have an undetectable HIV viral load, were interviewed.

The three key blind spots that affect the quality of life among PWH in Singapore, include:

1)  PWH prioritize short-term physical health over mental and psychosocial health
Consultation sessions between PWH in Singapore and their healthcare professionals center mainly around behaviors that will impact short-term health issues due to HIV, and few recognize that mental stressors such as external stigma and social anxiety can impact their immediate well-being. Notably, when being asked about the top five most important well-being indicators, the PWH interviewed ranked, in sequence, is 1) impact of symptoms and side effects of drugs, followed by 2) mood, 3) sleep, 4) body changes, and 5) energy, and agree that their mood impacts their social motivation and daily functioning. Even so, Singaporean patients highlighted that physicians placed the greatest emphasis on physical health and were less likely to focus on mental and social health in their discussions with patients.

2)  PWH have limited awareness of the appropriate care strategies on HIV-related comorbidities such as cardiovascular and other conditions
While PWH are aware of the importance of achieving holistic well-being by adopting healthier lifestyles, they generally have limited awareness of comorbidities risk associated with HIV, such as cardiovascular and other conditions. Inadequate communication between PWH and healthcare professionals can potentially compromise the effective management of their HIV. This is particularly evident when PWH lack awareness of specific symptoms and side effects. For example, some antiretroviral drugs used in HIV treatment may elevate the risk of cardiovascular disease and other conditions, thereby affecting the long-term health of PWH[1,2].

3)  PWH were relatively passive during communications with healthcare professionals
Research found that doctors are taking a leading role during consultation sessions, focusing on the physical conditions of the PWH, like viral load control and immune index. PWH are often passive recipients of information from healthcare professionals, and they tend to refrain from asking questions or raising concerns about HIV-related comorbidities, mental health, and psychosocial well-being. This limits communication effectiveness during consultation sessions and as a result, will impact treatment outcomes.

Dedicated mobile app to assist PWH with proactive health management

To order to assist PWH to communicate more effectively with their healthcare professionals, Gilead Sciences has recently launched the My Care Diary educational mobile app for PWH in Singapore. As a trusted source of disease awareness materials for PWH, the app deploys gamification features with animated avatars to increase engagement of interactive educational content which helps them plan conversations with healthcare professionals prior to medical appointments and reinforce the value of self-care and quality of life [see Note 2]. 

“The outlook for PWH has significantly improved and they can lead long and healthy lives. The research findings have demonstrated that more can be done to raise awareness of the long-term quality of life of PWH. Moreover, prioritizing psychosocial health well-being is an important aspect of the overall health management of PWH, as it could impact the treatment outcome, quality of life, and physical well-being,” said Dr. Asok Kurup, Infectious Disease Specialist from Mount Elizabeth.

“Our focus on patient-centricity is key to the delivery of quality care, which we strongly believe unlocks better health outcomes for all. This research helps us to understand PWH’s perception of health management, knowledge about chronic diseases, and the challenges they face so that we can further strengthen patient education through different channels. This not only improves the health management of PWH but also encourages them to play a more proactive role when communicating with healthcare professionals. Through this, PWH will be able to identify the most appropriate care strategies which can improve their physical and psychosocial health ultimately,” said Ms. Christina Yip, Senior Director, Medical Affairs, Gilead Sciences.

Mr. Chronos Kwok, Executive Director, Action for AIDS Singapore agreed that “Managing health and overall well-being can be sometimes overwhelming for PWH, especially those newly diagnosed. It is therefore important for community-based organizations to provide resources such as communication tools, and activities that can help foster effective engagement between PWH and their healthcare professionals. This can contribute to enhancing the confidence of PWH, especially on topics around HIV care, mental health, and social support, thus improving their overall quality of life in the long run.”

[Note] UNAIDS released its target of ’90-90-90′ in 2018 and the target was updated to ’95-95-95′ in 2021.

[Note 2] No personal identifiable information will be collected from users to protect the privacy of PWH. All contents on the App are disease awareness materials only and do not constitute medical advice. Users of the App are reminded to seek medical advice from their healthcare professionals.

[1] So-Armah K, et al. Lancet HIV. 2020 Apr;7(4):e279-e293

[2] Islam FM, et al. BMC Public Health. 2012 Mar 23;12:234.

About Gilead Sciences in HIV

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead was recognized as the number one philanthropic funder of HIV-related programs in a report released by Funders Concerned About AIDS.

Learn more about Gilead’s unique collaborations worldwide and the work to help end the global HIV epidemic.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. 

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on X (@GileadSciences)  and  LinkedIn or contact Gilead Public Affairs Asia 5 team at mediaasia@gilead.com. 

 

View original content:https://www.prnewswire.com/apac/news-releases/research-identifies-blind-spots-that-affect-quality-of-life-among-people-with-hiv-in-singapore-302200332.html

SOURCE Gilead Sciences, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ChipMOS EXPECTS 6.3% FULL YEAR 2024 REVENUE GROWTH, WITH A 5.4% YoY DECEMBER 2024 REVENUE DECLINE AND A 5.7% YoY 4Q24 REVENUE DECLINE

Published

on

By

HSINCHU, Jan. 10, 2025 /PRNewswire-FirstCall/ — ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services (“OSAT”), today reported its unaudited consolidated revenue for the month of December 2024 and for the fourth quarter ended December 31, 2024. All U.S. dollar figures cited in this press release are based on the exchange rate of NT$32.79 to US$1.00 as of December 31, 2024. This would represent full year 2024 revenue growth of approximately 6.3% compared to the full year 2023.

Revenue for the fourth quarter of 2024 was NT$5,399.6 million or US$164.7 million, representing a decrease of 5.7% from the fourth quarter of 2023, and a decrease of 11.0% from the third quarter of 2024. The Company noted that while the quarterly decline reflects macro industry pricing and demand headwinds, the strong full year 2024 revenue growth reflects continued leadership in its core markets.

Revenue for the month of December 2024 was NT$1,780.1 million or US$54.3 million, representing a decrease of 3.0% from November 2024, and a decrease of 5.4% from December 2023.

Consolidated Monthly Revenues (Unaudited)

December 2024

November 2024

December 2023

MoM Change

YoY Change

Revenues

   (NT$ million)

1,780.1

1,834.6

1,881.5

-3.0 %

-5.4 %

Revenues

   (US$ million)

54.3

55.9

57.4

-3.0 %

-5.4 %

 

Consolidated Quarterly Revenues (Unaudited)

Fourth Quarter

2024

Third Quarter

2024

Fourth Quarter

2023

QoQ Change

YoY Change

Revenues

   (NT$ million)

5,399.6

6,068.0

5,725.4

-11.0 %

-5.7 %

Revenues

   (US$ million)

164.7

185.1

174.6

-11.0 %

-5.7 %

About ChipMOS TECHNOLOGIES INC.:

ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS) (www.chipmos.com) is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS is known for its track record of excellence and history of innovation. The Company provides end-to-end assembly and test services to leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries serving virtually all end markets worldwide. 

Forward-Looking Statements:

This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future’ or similar expressions or by discussion of, among other things, strategies, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. Further information regarding these risks, uncertainties and other factors are included in the Company’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s other filings with the SEC.

Contacts:

In Taiwan

Jesse Huang

ChipMOS TECHNOLOGIES INC.

+886-6-5052388 ext. 7715

IR@chipmos.com

In the U.S.

David Pasquale

Global IR Partners

+1-914-337-8801

dpasquale@globalirpartners.com 

View original content:https://www.prnewswire.com/news-releases/chipmos-expects-6-3-full-year-2024-revenue-growth-with-a-5-4-yoy-december-2024-revenue-decline-and-a-5-7-yoy-4q24-revenue-decline-302347705.html

SOURCE ChipMOS TECHNOLOGIES INC.

Continue Reading

Technology

16 Press Releases You Need to See This Week

Published

on

By

Plus, press release highlights from CES 2025.

NEW YORK, Jan. 10, 2025 /PRNewswire/ — With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week’s most newsworthy and popular releases, here’s a recap of some major stories from the week that shouldn’t be missed.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

McDonald’s New McValue Platform Is Finally Here
Fans can mix and match with the new Buy One, Add One for $1 offer and fuel up for less with the popular $5 Meal Deal. The brand marks the moment by partnering with John Cena and gifting fans millions of dollars in entertainment, lifestyle promos.ADP National Employment Report: Private Sector Employment Increased by 122,000 Jobs in December; Annual Pay was Up 4.6%
“The labor market downshifted to a more modest pace of growth in the final month of 2024, with a slowdown in both hiring and pay gains,” said Nela Richardson, chief economist, ADP. “Health care stood out in the second half of the year, creating more jobs than any other sector.”Big Lots Closes Sale to Gordon Brothers Retail Partners
Bruce Thorn, Big Lots’ President and Chief Executive Officer, said, “We are pleased to close this strategic transaction, which provides a framework to preserve thousands of jobs, maximize value, and maintain the Big Lots brand.”Globally Renowned Investor and Entrepreneur Kevin O’Leary Joining The People’s Bid for TikTok
The bid aims to purchase TikTok’s U.S. assets and rebuild the platform in a way that prioritizes the privacy of its 170 million American users.NASA to Explore Two Landing Options for Returning Samples from Mars
“Pursuing two potential paths forward will ensure that NASA is able bring these samples back from Mars with significant cost and schedule saving compared to the previous plan,” said NASA Administrator Bill Nelson. “These samples have the potential to change the way we understand Mars, our universe, and – ultimately – ourselves.”Tripadvisor Reveals 2025’s Must-Visit Destinations: Top Picks From Travelers Around the World This year Tripadvisor introduces two new subcategories; Solo Travel Destinations and a special sub-category in celebration of Tripadvisor’s 25th anniversary honoring the Top Destinations of the Last 25 Years based on all time reviews.Ulta Beauty Teams Up with Instacart to Deliver Beauty in a Flash Nationwide
Beauty meets convenience with the largest specialty U.S. beauty retailer now available on Instacart for delivery in as fast as an hour from more than 1,400 stores.Nation’s Top 300 Teen Scientists Selected for Achievements in STEM Innovation and Leadership in Nation’s Oldest and Most Prestigious High School Competition
The 300 scholars will be awarded $2,000 each and their schools will be awarded $2,000 for each enrolled scholar. Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders.$5 Bowls with Five Choices: KFC® Debuts Hot New Lineup of Flavorful Bowls, Including Anticipated Return of Nashville Hot Sauce
Indulge your cravings with a hearty, warm, comforting bowl this winter for just $5 each, making your post-holiday wallet happy. Paramount and Comcast Announce Multi-Year Distribution Agreements
The multi-year deals feature ongoing carriage of Paramount’s networks, including CBS, BET, Comedy Central, MTV, Nickelodeon, Paramount Network and more. Comcast subscribers will also retain access to Paramount’s popular streaming services across Paramount+, Pluto TV and BET+.Michael J. Fox Honored with Presidential Medal of Freedom
President Biden presented Fox with the medal, which honors individuals who have made exemplary contributions to the prosperity, values, or security of the United States, world peace, or other significant societal, public or private endeavors.Hyundai Vehicles Available to “Add to Cart” on Amazon Autos
Car buyers around the U.S. can browse, order and finance any new Hyundai vehicle through a participating Hyundai dealer directly on Amazon Autos, and schedule a pickup from the dealer.The Latest Innovation from CHIPS AHOY! Is…Not A Cookie?! Introducing New CHIPS AHOY! Baked Bites – Bite-Sized Blondies to Satisfy Your Sweet Tooth
Baked into a square shape with a soft and chewy texture inspired by a brownie, CHIPS AHOY! Baked Bites, Blondie variety, are made with delicious, real chocolate chips and no high fructose corn syrup, offering an entirely reimagined CHIPS AHOY! experience. Buffalo thunders back as Zillow’s hottest market for 2025
“Shoppers nationwide should see more options for sale than in recent years, along with slow and steady price growth. That’s the good news. But both buyers and sellers should expect unpredictable mortgage rates,” said Skylar Olsen, Zillow chief economist.Girl Scouts’ 2025 Cookie Season Kicks Off Nationally, Helping Girls Across the Country Unbox Brighter Futures for Themselves
At the close of the 2025 cookie season, two beloved cookie flavors, Girl Scout S’mores® and Toast-Yay!®, will be retired.United Announces Accelerated Timeline for Starlink’s Industry-Leading Connectivity in the Sky
The airline now expects to begin testing Starlink next month with the first commercial flight anticipated to take off this spring on a United Embraer E-175 aircraft. Ultimately, United will add Starlink to its entire fleet.

Read more of the latest releases from PR Newswire.

Do you have a press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

CES 2025

CES took over Las Vegas — and the wire — this week as companies from a range of industries shared news of their latest consumer technology innovations. From advances in mobility and AI to medtech, smart homes and much more, PR Newswire is here to help journalists and consumers keep track of the announcements tied to the consumer electronics tradeshow.

Here are just a few of the big CES press releases sent this week:

What Not to Miss at CES 2025XREAL Announces Groundbreaking Collaborations at CES 2025EcoFlow Debuts AI-Powered OASIS at CES 2025, Maximizing Energy Savings and Extreme Weather PrepSony Exhibits at CES® 2025Exclusive to CES 2025: Bird Buddy Goes Beyond Birds with New Wonder Nature Tech Product Announcement

Catch up on the latest CES 2025 announcements.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they’re signed up, reporters, bloggers, and freelancers have access to the following free features:

Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger’s next story.Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

For questions, contact the team at media.relations@cision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/16-press-releases-you-need-to-see-this-week-302347612.html

SOURCE PR Newswire

Continue Reading

Technology

Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China

Published

on

By

RA’ANANA, Israel, Jan. 10, 2025 /PRNewswire/ — Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing need for advanced respiratory care technologies globally.

Inspira is already in discussions with leading providers in affected regions to evaluate demand for advance respiratory solutions and deployment of the INSPIRA™ ART100 device, ensuring rapid response capabilities in case of increased demand.

As global health authorities monitor the hMPV outbreak, Inspira™ believes that it is well-positioned to meet potential increased demand for advanced respiratory support systems. Inspira is working closely with suppliers to secure necessary raw materials and components to meet potential demand spikes. The Company is following the hMPV situation globally and working to adjust production plans as needed.

“While hMPV is not a new virus, and experts indicate the current outbreak is part of normal seasonal patterns, Inspira believes in being prepared,” said Dagi Ben-Noon, CEO of Inspira. “Our increased production capacity will help ensure healthcare providers have access to vital respiratory care equipment should the need arise.”

Inspira emphasizes that its preparedness measures are precautionary and align with the Company’s commitment to global health readiness. The Company will work closely with health authorities in affected regions and adjust its plans based on the evolving situation.

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake during treatment. The INSPIRA ART is being equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient’s condition without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions.

In June and July 2024, respectively, the Company’s INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company’s other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans nor approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the growing need for advanced respiratory care technologies and its ability to adjust its plans to rapidly respond in case of increased demand. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.

Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

MRK-ARS-113

Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/inspira-preparing-production-in-response-to-spread-of-respiratory-virus-in-china-302347881.html

SOURCE Inspira Technologies

Continue Reading

Trending